Atsushi Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Atsushi Sato has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Daisuke Kurimoto
School of Bioscience and Biotechnology Tokyo University of Technology Japan
6 shared publicationsDaisuke Murata
School of Bioscience and Biotechnology, Tokyo University of Technology, 1404-1, Katakura, Hachioji, Tokyo, 192-0982, Japan
3 shared publicationsShinji Kagaya
NRL Pharma, Inc., Kawasaki, Kanagawa, 213-0012, Japan
3 shared publicationsTakashi Takeuchi
Department of Veterinary Medicine, Tottori University, Koyama-Minami, Tottori, 680-8553, Japan
3 shared publicationsYuki Shiga
School of Bioscience and Biotechnology, Tokyo University of Technology, 1404-1, Katakura, Hachioji, Tokyo, 192-0982, Japan
3 shared publicationsAkinori Sugimoto
School of Bioscience and Biotechnology, Tokyo University of Technology , Hachioji, Tokyo 192-0982, Japan
2 shared publications
Latest Publications
- Open Access
- 24 March 2026
- Published by Wiley in FEBS Open Bio
- Vol. 16 (9) , 1786-1800
Suppression of lung adenocarcinoma migration through organelle alkalization by human lactoferrin – albumin fusion
The fusion of human serum albumin with human lactoferrin (hLF‐HSA) exerts strong anti‐migratory effects in human lung adenocarcinoma cells through matrix metalloproteinase 1 (MMP1) downregulation. We demonstrate that hLF‐HSA disrupts organelle pH homeostasis via Na + /H + exchanger 7 (NHE7) upregulation, inducing organelle alkalization in the Golgi apparatus. This organelle dysfunction alters the Golgi‐mediated secretome, leading to MMP1 downregulation and suppression of cell migration. hLF‐HSA‐induced MMP1 downregulation also reverses epithelial‐mesenchymal transition (EMT), further suppressing migration. Additionally, hLF‐HSA‐driven activation of caveolae‐mediated endocytosis (CavME) signaling downregulated MMP1 expression without NHE7 upregulation. These findings highlight that hLF‐HSA–mediated disruption of organelle pH regulation and CavME activation represents a potential strategy to suppress cancer cell migration. Impact statement: This work reveals a previously unrecognized link between organelle pH dysregulation and cancer cell migration. By identifying hLF‐HSA as a dual modulator of Golgi function and endocytic signaling, it provides a mechanistic basis for developing novel anti‐metastatic strategies targeting intracellular trafficking rather than cytotoxicity.
- 24 March 2026
- Published by Wiley in FEBS Open Bio
- Vol. 16 (9) , 1786-1800
Open AccessSuppression of lung adenocarcinoma migration through organelle alkalization by human lactoferrin – albumin fusion
The fusion of human serum albumin with human lactoferrin (hLF‐HSA) exerts strong anti‐migratory effects in human lung adenocarcinoma cells through matrix metalloproteinase 1 (MMP1) downregulation. We demonstrate that hLF‐HSA disrupts organelle pH homeostasis via Na + /H + exchanger 7 (NHE7) upregulation, inducing organelle alkalization in the Golgi apparatus. This organelle dysfunction alters the Golgi‐mediated secretome, leading to MMP1 downregulation and suppression of cell migration. hLF‐HSA‐induced MMP1 downregulation also reverses epithelial‐mesenchymal transition (EMT), further suppressing migration. Additionally, hLF‐HSA‐driven activation of caveolae‐mediated endocytosis (CavME) signaling downregulated MMP1 expression without NHE7 upregulation. These findings highlight that hLF‐HSA–mediated disruption of organelle pH regulation and CavME activation represents a potential strategy to suppress cancer cell migration. Impact statement: This work reveals a previously unrecognized link between organelle pH dysregulation and cancer cell migration. By identifying hLF‐HSA as a dual modulator of Golgi function and endocytic signaling, it provides a mechanistic basis for developing novel anti‐metastatic strategies targeting intracellular trafficking rather than cytotoxicity.
- Top Cited PapersOpen Access
- 10 February 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (5) , 567-577
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL
PURPOSE: The JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework. PATIENTS AND METHODS: Patients age 1-19 years with newly diagnosed B-ALL were enrolled in this study. These patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups. Randomized comparisons assessed the effectiveness of vincristine (VCR)/dexamethasone pulses in the SR group, evaluated the effects of L-asparaginase (ASP) intensification in the IR group, and compared standard consolidation including block-type treatment with experimental consolidation with high-dose methotrexate (HD-MTX) intensified with VCR and ASP in the HR group. RESULTS: Of 1,936 patients enrolled, 1,804 were eligible for the experimental treatment. The overall 5-year event-free survival and overall survival rates were 85.2% (95% CI, 83.5 to 86.8) and 94.3% (95% CI, 93.1 to 95.3), respectively. The cumulative incidence of relapse and postremission nonrelapse mortality was 13.2% (95% CI, 11.6 to 14.8) and 0.6% (95% CI, 0.3 to 1.0), respectively. Random assignment in the SR group showed no significant benefit from pulse therapy. In the IR group, ASP intensification had limited effects. In the HR group, standard block therapy and HD-MTX yielded equivalent outcomes. CONCLUSION: The ALL-B12 trial achieved favorable outcomes in a nationwide cohort by stratifying treatment on the basis of risk and balancing treatment intensity. This study not only demonstrated that existing standard of care can be further refined but also indicated that improvement in outcomes with intensified chemotherapy has reached a plateau.
- 10 February 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (5) , 567-577
Top Cited PapersOpen AccessJCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL
PURPOSE: The JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework. PATIENTS AND METHODS: Patients age 1-19 years with newly diagnosed B-ALL were enrolled in this study. These patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups. Randomized comparisons assessed the effectiveness of vincristine (VCR)/dexamethasone pulses in the SR group, evaluated the effects of L-asparaginase (ASP) intensification in the IR group, and compared standard consolidation including block-type treatment with experimental consolidation with high-dose methotrexate (HD-MTX) intensified with VCR and ASP in the HR group. RESULTS: Of 1,936 patients enrolled, 1,804 were eligible for the experimental treatment. The overall 5-year event-free survival and overall survival rates were 85.2% (95% CI, 83.5 to 86.8) and 94.3% (95% CI, 93.1 to 95.3), respectively. The cumulative incidence of relapse and postremission nonrelapse mortality was 13.2% (95% CI, 11.6 to 14.8) and 0.6% (95% CI, 0.3 to 1.0), respectively. Random assignment in the SR group showed no significant benefit from pulse therapy. In the IR group, ASP intensification had limited effects. In the HR group, standard block therapy and HD-MTX yielded equivalent outcomes. CONCLUSION: The ALL-B12 trial achieved favorable outcomes in a nationwide cohort by stratifying treatment on the basis of risk and balancing treatment intensity. This study not only demonstrated that existing standard of care can be further refined but also indicated that improvement in outcomes with intensified chemotherapy has reached a plateau.
- 5 January 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 695, 149480
Intracellularly delivered human lactoferrin functions as an activator of Na+/H+ exchanger 7
- 5 January 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 695, 149480
Intracellularly delivered human lactoferrin functions as an activator of Na+/H+ exchanger 7
- Open Access
- 22 September 2023
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 191, 106591
Enhanced intracellular uptake of an albumin fusion protein in cancer cells by its forced cell surface recruitment
- 22 September 2023
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 191, 106591
Open AccessEnhanced intracellular uptake of an albumin fusion protein in cancer cells by its forced cell surface recruitment
- 27 September 2022
- Published by Springer Nature in BioMetals
- Vol. 36 (3) , 629-638
Albumin fusion with human lactoferrin shows enhanced inhibition of cancer cell migration
The fusion of human serum albumin (HSA) with human lactoferrin (hLF) (designated as hLF-HSA) has improved the pharmacokinetic properties and anti-proliferative activities of hLF against cancer cells. In this study, we evaluated the anti-migratory activities of hLF and hLF-HSA against the human lung adenocarcinoma PC-14 cell line using wound healing and Boyden chamber assays. Despite the unexpected hLF-induced migration, hLF-HSA clearly demonstrated the complete inhibition of PC-14 cell migration. To examine the mechanism underlying the enhanced PC-14 cell migration by hLF alone but suppressed migration by hLF-HSA, we focused on the matrix metalloproteinase (MMP) family of endopeptidases because MMPs are often reported to play important roles in facilitating the migration and metastasis of cancer cells. Furthermore, hLF is a transactivator of MMP1 transcription. As expected, treatment of cells with hLF and hLF-HSA led to the upregulation and downregulation of MMP1, respectively. In contrast, MMP9 expression levels, which are often associated with cancer migration, were unchanged in the presence of either protein. An MMP inhibitor attenuated hLF-induced migration of PC-14 cells. Therefore, specific enhancement and suppression of MMP1 expression by hLF and hLF-HSA have been implicated as causes of a marked increase and decrease in PC-14 cell migration, respectively. In conclusion, the fusion of HSA with hLF (hLF-HSA) promoted its anti-migratory effects against cancer cells. Therefore, hLF-HSA is a promising anti-cancer drug candidate based on its improved anti-migratory activity towards cancer cells.
- 27 September 2022
- Published by Springer Nature in BioMetals
- Vol. 36 (3) , 629-638
Albumin fusion with human lactoferrin shows enhanced inhibition of cancer cell migration
The fusion of human serum albumin (HSA) with human lactoferrin (hLF) (designated as hLF-HSA) has improved the pharmacokinetic properties and anti-proliferative activities of hLF against cancer cells. In this study, we evaluated the anti-migratory activities of hLF and hLF-HSA against the human lung adenocarcinoma PC-14 cell line using wound healing and Boyden chamber assays. Despite the unexpected hLF-induced migration, hLF-HSA clearly demonstrated the complete inhibition of PC-14 cell migration. To examine the mechanism underlying the enhanced PC-14 cell migration by hLF alone but suppressed migration by hLF-HSA, we focused on the matrix metalloproteinase (MMP) family of endopeptidases because MMPs are often reported to play important roles in facilitating the migration and metastasis of cancer cells. Furthermore, hLF is a transactivator of MMP1 transcription. As expected, treatment of cells with hLF and hLF-HSA led to the upregulation and downregulation of MMP1, respectively. In contrast, MMP9 expression levels, which are often associated with cancer migration, were unchanged in the presence of either protein. An MMP inhibitor attenuated hLF-induced migration of PC-14 cells. Therefore, specific enhancement and suppression of MMP1 expression by hLF and hLF-HSA have been implicated as causes of a marked increase and decrease in PC-14 cell migration, respectively. In conclusion, the fusion of HSA with hLF (hLF-HSA) promoted its anti-migratory effects against cancer cells. Therefore, hLF-HSA is a promising anti-cancer drug candidate based on its improved anti-migratory activity towards cancer cells.
- 1 March 2022
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 45 (3) , 284-291
Improved Refolding of a Human IgG1 Fc (CH2-CH3) Scaffold from Its Inclusion Body in E. coli by Alkaline Solubilization
Recently, we developed a platform strategy for hinge-deficient human immunoglobulin G1 (IgG1) Fc fusion as a non-immunostimulatory Fc fusion system. As a starting point to establish a promising approach for generating hinge-deficient Fc fusion proteins in Escherichia (E.) coli, we selected a CH2-CH3 scaffold as a model protein for evaluation. Recombinant CH2-CH3, expressed as inclusion bodies, was solubilized with various denaturants (urea, sarkosyl, sodium dodecyl sulfate (SDS), 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), or Triton X-100) in neutral (phosphate-buffered saline (PBS), pH 8) or alkaline (50 or 500 mM N-cyclohexyl-3-aminopropanesulfonic acid (CAPS), pH 11) buffer at 25 °C. Similar to the authentic CH2-CH3 produced in Chinese hamster ovary (CHO) cells, all denaturants, except urea in CAPS buffer but not in PBS, were found to elicit the dimer formation of solubilized CH2-CH3 on SDS-polyacrylamide gel electrophoresis (PAGE). After dialysis with PBS, sarkosyl-soluble CH2-CH3 inclusion bodies were successfully purified using protein G-Sepharose, indicating their successful refolding. Compared to the purified CH2-CH3 from its sarkosyl-soluble inclusion bodies in neutral buffer, that in 500 mM CAPS alkaline buffer revealed substantial structure-related similarities, such as secondary structures and thermal stabilities, as measured by circular dichroism spectroscopy, to authentic CH2-CH3. Native PAGE analysis also supported the above data. Therefore, solubilization at alkaline pH is an essential factor that promotes the refolding of CH2-CH3. Dimer formation of CH2-CH3 on SDS-PAGE may act as a surrogate marker for its protein refolding status. Our observations may provide important hints toward downstream processing of Fc-fusion production in E. coli.
- 1 March 2022
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 45 (3) , 284-291
Improved Refolding of a Human IgG1 Fc (CH2-CH3) Scaffold from Its Inclusion Body in E. coli by Alkaline Solubilization
Recently, we developed a platform strategy for hinge-deficient human immunoglobulin G1 (IgG1) Fc fusion as a non-immunostimulatory Fc fusion system. As a starting point to establish a promising approach for generating hinge-deficient Fc fusion proteins in Escherichia (E.) coli, we selected a CH2-CH3 scaffold as a model protein for evaluation. Recombinant CH2-CH3, expressed as inclusion bodies, was solubilized with various denaturants (urea, sarkosyl, sodium dodecyl sulfate (SDS), 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), or Triton X-100) in neutral (phosphate-buffered saline (PBS), pH 8) or alkaline (50 or 500 mM N-cyclohexyl-3-aminopropanesulfonic acid (CAPS), pH 11) buffer at 25 °C. Similar to the authentic CH2-CH3 produced in Chinese hamster ovary (CHO) cells, all denaturants, except urea in CAPS buffer but not in PBS, were found to elicit the dimer formation of solubilized CH2-CH3 on SDS-polyacrylamide gel electrophoresis (PAGE). After dialysis with PBS, sarkosyl-soluble CH2-CH3 inclusion bodies were successfully purified using protein G-Sepharose, indicating their successful refolding. Compared to the purified CH2-CH3 from its sarkosyl-soluble inclusion bodies in neutral buffer, that in 500 mM CAPS alkaline buffer revealed substantial structure-related similarities, such as secondary structures and thermal stabilities, as measured by circular dichroism spectroscopy, to authentic CH2-CH3. Native PAGE analysis also supported the above data. Therefore, solubilization at alkaline pH is an essential factor that promotes the refolding of CH2-CH3. Dimer formation of CH2-CH3 on SDS-PAGE may act as a surrogate marker for its protein refolding status. Our observations may provide important hints toward downstream processing of Fc-fusion production in E. coli.
- 2 December 2021
- Published by International Display Workshops General Incorporated Association in Proceedings of the International Display Workshops
- p. 276
Wavelength Dispersion Control of Three-Dimensional Birefringence in Retardation Film for VA-LCD
Proceedings of the International Display Workshops Volume 28 (IDW '21),Search for presentations
- 2 December 2021
- Published by International Display Workshops General Incorporated Association in Proceedings of the International Display Workshops
- p. 276
Wavelength Dispersion Control of Three-Dimensional Birefringence in Retardation Film for VA-LCD
Proceedings of the International Display Workshops Volume 28 (IDW '21),Search for presentations
- 1 January 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 534, 1076-1082
Harnessing the chondroitin sulfate-binding characteristics of human lactoferrin to neutralize neurite outgrowth inhibition
- 1 January 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 534, 1076-1082
Harnessing the chondroitin sulfate-binding characteristics of human lactoferrin to neutralize neurite outgrowth inhibition